NextPharma Oy
NextPharma Oy is a Finnish-headquartered European CDMO operating nine specialized manufacturing facilities across Germany, the UK, France, Finland, and Norway, providing pharmaceutical development, manufacturing, and packaging services to biotech and pharmaceutical innovators.
- Company typePrivate
- Founded-
- HeadquartersBerlin, Germany
- Headcount51–100
- GTM typeB2B
- OfferingServices
What NextPharma Oy does
NextPharma Oy is a Finnish-incorporated Contract Development and Manufacturing Organization (CDMO) headquartered in Tampere that delivers pharmaceutical development, manufacturing, and packaging services to pharmaceutical companies, biotech innovators, and health-and-nutrition firms. The company operates nine specialized Centres of Excellence across five European countries — Germany, the United Kingdom, France, Finland, and Norway — each dedicated to specific drug-delivery formats: penicillins (Berlin), modified-release formulations and analytical services (Bielefeld), solids and clinical-trial supply plus cephalosporins (Göttingen), hormones and semi-solids (Waltrop), liquid-filled hard capsules (Edinburgh), liquids and suppositories (Limay), lipid-based formulations and softgels (Ploërmel), ophthalmics (Tampere), and chewable tablets (Asker). This format-by-site specialization is the core technical architecture of the business.
The company's service portfolio spans five integrated lines: Pharmaceutical Development (formulation, analytical development, process optimization), Clinical Trials Services (clinical-trial supply), Commercial Manufacturing & Packaging, Health & Nutrition (food-supplement CDMO), and Analytical & Microbiological Services. Revenue is generated through B2B contract manufacturing engagements on a quote-based, project-and-volume pricing model, with go-to-market executed via direct enterprise sales supplemented by participation in major industry trade shows (CPHI, Vitafoods, Outsourcing in Clinical Trials).
In October 2025 NextPharma divested its logistics arm to Cencora and appointed Ajeeth Enjeti as CEO succeeding Peter Burema, repositioning the business as a pure-play European CDMO. The company emphasizes regulatory compliance (GMP) for highly controlled categories including antibiotics and hormones, and positions speed, flexibility, and a one-global-team approach as primary value propositions for sponsor customers.
NextPharma Oy firmographics
Firmographics- Name
- NextPharma Oy
- Legal name
- NextPharma Oy
- Website
- https://nextpharma.fi
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- NextPharma Oy is a Finnish-headquartered European CDMO operating nine specialized manufacturing facilities across Germany, the UK, France, Finland, and Norway, providing pharmaceutical development, manufacturing, and packaging services to biotech and pharmaceutical innovators.
- Ownership category
- akta.pro rank
NextPharma Oy industry classification
Industry- Product category
- Pharmaceutical CDMO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where NextPharma Oy is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices9 records
Markets served
NextPharma Oy business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Development and Manufacturing Services: NextPharma generates revenue through providing contract development and manufacturing services to pharmaceutical and nutraceutical companies. Revenue comes from pharmaceutical development services, clinical trials supply services, commercial manufacturing and packaging, and analytical/microbiological testing services.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
NextPharma Oy product offering
Product offeringCore offering
NextPharma Oy is a Contract Development and Manufacturing Organization (CDMO) providing pharmaceutical development, clinical trial supply, commercial manufacturing and packaging, and analytical/microbiological services to biotech, pharmaceutical, and nutritional supplement companies. The company operates 9 Centres of Excellence across Europe (Germany, UK, France, Finland, Norway) specialising in multiple dosage forms including penicillins, cephalosporins, modified release, softgels, ophthalmics, hormones, chewable tablets, liquids, and suppositories. Services span early-stage drug development through to commercial supply, delivered under a one global team model with integrated quality control testing.
Product overview
NextPharma is a Contract Development and Manufacturing Organization (CDMO) offering an integrated portfolio of pharmaceutical development and manufacturing services across Europe. The company provides five core service lines: Pharmaceutical Development (formulation and process support from early stages to manufacturing), Clinical Trials Services (supply chain for clinical studies), Commercial Manufacturing & Packaging (large-scale production), Health and Nutrition (food supplements CDMO services), and Analytical and Microbiological Services (quality control testing). These services are delivered through a network of ten Centres of Excellence located across Europe (Germany, UK, France, Norway, Finland), each specializing in specific dosage forms including penicillins, cephalosporins, modified release formulations, liquid-filled hard capsules, softgels, liquids, suppositories, hormones, semi-solids, ophthalmics, and chewable tablets. The company positions itself as a one global team partner with customers at the centre of everything they do, offering fast, flexible, and tailored solutions for markets worldwide.
Differentiator
Problem solved
Functional benefit
Products and services
- Pharmaceutical Development Expert CDMO support for drug development projects from early stages through to manufacturing, covering formulation, analytical development, and process optimisation for biotech and pharmaceutical companies.
- Clinical Trials Services Flexible and reliable clinical trials supply services for biotech and pharmaceutical companies conducting human trials, including supply chain and packaging support.
- Commercial Manufacturing & Packaging Contract manufacturing services for commercial pharmaceutical supply, covering solid dosage forms, liquids, and packaging solutions for biotech and pharmaceutical companies requiring commercial-scale production.
- Health and Nutrition European contract development and manufacturing services for food supplements and nutritional products, serving health and nutrition companies seeking a European-based manufacturing partner.
- Analytical and Microbiological Services Comprehensive analytical and microbiological testing services that support pharmaceutical development and manufacturing quality control, offered as part of NextPharma's integrated CDMO service portfolio.
Companies that use NextPharma Oy
Customer profileSegments2 records
Ideal customer profiles2 records
NextPharma Oy technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature10 records
NextPharma Oy partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CencoramajorNextPharma sold its logistics arm to Cencora as part of a strategic plan to position NextPharma as Europe's leading pure-play CDMO. This divestment represents a significant strategic realignment focusing on core pharmaceutical development and manufacturing services.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
NextPharma Oy competitors and assessment
Company assessmentDirect peers
- Recipharm: Swedish-headquartered pan-European CDMO with multiple manufacturing sites across Europe offering solid dose, sterile, semi-solid and inhalation capabilities. Competes head-to-head with NextPharma for biotech and pharma contract manufacturing contracts across the same European customer base.
- Fareva: French privately-held CDMO with broad European manufacturing footprint spanning sterile injectables, liquids, ointments, and active ingredients. Direct competitor for European pharmaceutical contract manufacturing contracts, particularly in liquid and semi-solid dosage forms where both companies overlap.
- Aenova Group: German-headquartered CDMO with comparable pan-European manufacturing footprint and similar specialization in solid dosage forms, softgel capsules, and antibiotic production, including dedicated penicillins facilities. Operates as a direct competitor for European pharma contract manufacturing contracts across multiple dosage formats.
- Siegfried Holding: Swiss-listed CDMO specializing in API manufacturing and finished dosage forms across European and US sites, including controlled substances and steroids. Competes with NextPharma in commercial manufacturing and packaging for both branded and generic pharma customers.
- Almac Group: Northern Ireland-headquartered CDMO with integrated API development, formulation, clinical supply, commercial manufacturing and analytical services across UK and Ireland sites. Directly comparable service portfolio to NextPharma including similar packaging, CTS and QC capabilities.
- CordenPharma: European CDMO spun out of Roche offering API synthesis, peptide/lipid manufacturing, oral solid dose and sterile injectables across multiple European sites. Directly competes with NextPharma in formulation, manufacturing services and specialized drug delivery formats for pharma customers.
Broad incumbents
- Lonza Group: Swiss-listed global CDMO leader with extensive small-molecule API, oral dosage and biologics manufacturing capabilities across Europe and the US. Represents the broad incumbent competitor for both API and drug product contracts that NextPharma targets.
- Thermo Fisher Scientific (Patheon): Through its Patheon CDMO business, Thermo Fisher operates one of the largest global pharmaceutical contract manufacturing networks across APIs, oral solid dose, sterile fill-finish and biologics. Competes for the same enterprise pharma customers as NextPharma in commercial manufacturing.
- WuXi STA (WuXi AppTec): China-headquartered global CDMO offering API development, manufacturing and drug product services with growing European footprint through STA Pharma. Represents the emerging global-scale competitor targeting biotech and pharma outsourcing contracts that NextPharma also serves.
- Catalent (Novo Holdings): One of the largest global CDMOs offering softgel, oral solid dose, biologics and sterile fill-finish across dozens of sites worldwide. Competes with NextPharma for European commercial manufacturing contracts but at much larger scale across broader dosage formats and geographies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
NextPharma Oy social profiles
Digital presenceNextPharma Oy financial estimates
Financial estimateRevenue estimate
Valuation estimate
NextPharma Oy leadership team
Management profileNumber of profiles
Profiles1 record
NextPharma Oy funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NextPharma Oy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NextPharma Oy
What does NextPharma Oy do?
NextPharma Oy is a Contract Development and Manufacturing Organization (CDMO) providing pharmaceutical development, clinical trial supply, commercial manufacturing and packaging, and analytical/microbiological services to biotech, pharmaceutical, and nutritional supplement companies. The company operates 9 Centres of Excellence across Europe (Germany, UK, France, Finland, Norway) specialising in multiple dosage forms including penicillins, cephalosporins, modified release, softgels, ophthalmics, hormones, chewable tablets, liquids, and suppositories. Services span early-stage drug development through to commercial supply, delivered under a one global team model with integrated quality control testing.
Is NextPharma Oy a public or private company?
NextPharma Oy is a private company. It is classified as unknown and is currently operating.
When was NextPharma Oy founded?
NextPharma Oy was founded in -1. It employs 51 to 100 people.
Where is NextPharma Oy based?
NextPharma Oy is headquartered in Berlin, Germany, in the Europe region.
How does NextPharma Oy make money?
One revenue line is on record: contract Development and Manufacturing Services.
Who are NextPharma Oy's main competitors?
Direct peers on record are Recipharm, Fareva, Aenova Group, Siegfried Holding, Almac Group and CordenPharma. Broad incumbents are Lonza Group, Thermo Fisher Scientific (Patheon), WuXi STA (WuXi AppTec) and Catalent (Novo Holdings).
Does NextPharma Oy have an API?
No public API is recorded for NextPharma Oy.
What industry is NextPharma Oy in?
NextPharma Oy's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.